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Abstract
Background: Gag protein from HIV-1 is a polyprotein of 55 kDa, which, during viral maturation,
is cleaved to release matrix p17, core p24 and nucleocapsid proteins. The p24 antigen contains
epitopes that prime helper CD4 T-cells, which have been demonstrated to be protective and it can
elicit lymphocyte proliferation. Thus, p24 is likely to be an integral part of any multicomponent HIV
vaccine. The availability of an optimal adjuvant and carrier to enhance antiviral responses may
accelerate the development of a vaccine candidate against HIV. The aim of this study was to
investigate the adjuvant-carrier properties of the B ricin subunit (RTB) when fused to p24.
Results: A fusion between ricin toxin B subunit and p24 HIV (RTB/p24) was expressed in E. coli.
Affinity chromatography was used for purification of p24 alone and RTB/p24 from cytosolic
fractions. Biological activity of RTB/p24 was determined by ELISA and affinity chromatography using
the artificial receptor glycoprotein asialofetuin. Both assays have demonstrated that RTB/p24 is
able to interact with complex sugars, suggesting that the chimeric protein retains lectin activity.
Also, RTB/p24 was demonstrated to be immunologically active in mice. Two weeks after
intraperitoneal inoculation with RTB/p24 without an adjuvant, a strong anti-p24 immune response
was detected. The levels of the antibodies were comparable to those found in mice immunized with
p24 alone in the presence of Freund adjuvant. RTB/p24 inoculated intranasally in mice, also elicited
significant immune responses to p24, although the response was not as strong as that obtained in
mice immunized with p24 in the presence of the mucosal adjuvant cholera toxin.
Conclusion: In this work, we report the expression in E. coli of HIV-1 p24 fused to the subunit B
of ricin toxin. The high levels of antibodies obtained after intranasal and intraperitoneal
immunization of mice demonstrate the adjuvant-carrier properties of RTB when conjugated to an
HIV structural protein. This is the first report in which a eukaryotic toxin produced in E. coli is
employed as an adjuvant to elicit immune responses to p24 HIV core antigen.
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Background
Gag protein from HIV-1 is a polyprotein of 55 kDa which,
during viral maturation, is cleaved to release matrix pro-
tein p17, core protein p24 and nucleocapsid protein [1].
Antibodies elicited by the core p24 antigen are an early
marker of HIV infection and thereby constitute a major
target for HIV diagnosis in early stages of the infection [2].
Antiretroviral drugs can reduce circulating levels of p24
and consequently this antigen can also be used as a
marker for evaluating the efficacy of therapy [3,4]. The
p24 antigen can elicit lymphocyte proliferation responses,
which have been demonstrated to be protective, and it
also contains epitopes that prime helper CD4 T-cell
responses [5,6]. Thus, p24 is likely to be an integral part
of any multicomponent vaccine [7]. Recent trials have
suggested that HIV-specific cytotoxic T-lymphocyte activ-
ity can be increased in HIV-infected individuals receiving
p24 and the antiviral drug zidovudine, reinforcing the
possibility for a p24-containing therapeutic vaccine
against HIV in the presence of antiretroviral therapy [8].
Ribosome inactivating proteins are a group of cytotoxic
proteins. Ricin, the most toxic member of the group, accu-
mulates to high levels in the endosperm of Ricinus commu-
nis seeds [9]. It is a heterodimeric protein, comprising
subunits A and B. Ricin subunit A (RTA) of 31 kDa, is the
toxic component of the heterodimer and causes ribosome
inactivation, whereas subunit B (RTB) of 34 kDa, is a lec-
tin with galactose-binding properties, responsible for
attachment to the surface of target cells [9,10]. Previous
experiments had demonstrated that RTB delivers RTA to
the cytoplasm of target cells by interacting with glycopro-
teins and glycolipids located at the cell surface, thereby
triggering the endocytic pathway [11,12], via a still
unknown receptor [13]. This characteristic has prompted
experiments for RTB to be employed as a novel antigen
deliverer, leading to the hypothesis that this lectin repre-
sents a novel adjuvant-carrier.
On the other hand, the lack of an optimal adjuvant and
carrier to enhance antiviral responses has been problem-
atic in vaccine development against HIV [14]. The use of
adjuvant-carrier molecules fused to p24 to enhance pres-
entation to the immune system has only been explored on
three occasions, employing cholera toxin (CT) subunit B
[15], hepatitis B (HB) core antigen [16] and HSP70 from
Mycobacterium tuberculosis [14]. In this report, we
employed a RTB/p24 protein fusion to investigate biolog-
ical activity in vitro and to determine whether the presence
of RTB enhances immunological responses to p24 in
mice.
Results
Construction of RTB/p24 and p24 genes
The gene fragments p24 and RTB/p24 were cloned by
PCR. The core domain p24 was genetically fused to the 3'
region of RTB and cloned in a E. coli expression vector
(Figure 1). The constructs obtained, pTrcHisA-RTB/p24
and pTrcHisA-p24, were subjected to restriction enzyme
analysis. The constructs were fully sequenced to confirm
in-frame fusion of the two sequences (data not shown).
The molecular weight mass of the predicted translation
products from sequences RTB/p24 and p24 was 57 kDa
and 34 kDa respectively.
E. coli expression of RTB/p24 and p24 proteins
Purification of RTB/p24 and p24 was performed from cell
lysates in non-denaturing conditions to keep the proteins
in native conformation. In preliminary experiments, we
had tested the pellet and supernatant fractions after a 5 h
induction, to estimate the solubility of the recombinant
proteins. Expression was performed in six E. coli strains
Expression vectors Figure 1
Expression vectors. Map showing the constructs employed for E. coli expression in vector pTrcHis. (A) RTB/p24 and (B) 
p24. The histidine tag is indicated.
(A)
(B)
trc promoter 6xHIS p24
XhoI HindIII
pTrcHis A
p24 RTB 6xHIS trc promoter
EcoRI HindIII
XhoI / SalI
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grown at one of two temperatures (21°C or 37°C). The
optimal temperature for obtaining the highest recom-
binant protein levels for both RTB/p24 and p24 HIV was
37°C. We found that p24 is highly soluble (Figure 2,
panel A), whereas RTB/p24 was somewhat insoluble,
since we detected high concentration of this protein in the
pellet fractions after 5 h induction (Figure 2, panel E).
When comparing gene expression in the different E. coli
strains, p24 was expressed at the highest level in strain
HMS Rossetta 2 after 5 h induction (Figure 2, panel A).
Interestingly, the same strain was the best expressor for
RTB/p24 (Figure 2, panels B and C).
Purification of E. coli expressed p24 HIV and chimeric 
RTB/p24 proteins
In order to improve solubilization of the E. coli-produced-
RTB/p24 during affinity chromatography, we tested differ-
ent NaCl concentrations in combination with different
pH until an optimal buffer composition was determined
(50 mM TrisHCl, 300 mM NaCl, 20 mM Imidazole, 1 mM
PMSF, pH 7.0). Using these conditions, we routinely
obtained maximal solubilization of RTB/p24 (Figure 2,
panel D) and purification of both proteins was straight-
forward. The p24 protein, presenting a mw of approxi-
mately 34 kDa because of the histidine tag, yields only
one band on SDS-PAGE whereas the RTB/p24 fusion,
yields a mw of approximately 57 kDa (Figure 3, panel A).
Protein concentration was estimated by using a standard
curve of bovine serum albumin. Yields of p24 and RTB/
p24 recombinant proteins were estimated at 4.6 mg/l and
0.63 mg/l respectively.
Immunoblot analysis
Analysis by immunoblot of the recombinant purified pro-
teins p24 and RTB/p24 was performed to confirm the
identity of the proteins. A band of 34 kDa was detected by
specific anti-p24 antibodies although some lower bands
were also evident which, we hypothesize, are degradation
products. The RTB/p24 fusion was detected by three dif-
ferent antibodies, the monoclonal anti-p24, monoclonal
anti-His, and polyclonal anti-ricin antibodies. In all three
cases, a band of 57 kDa was detected. The fact that we were
able to detect the same band by three different antibodies
targeting different components of the chimeric RTB/p24
protein, demonstrate the integrity of the protein after
purification (Figure 3, panel C).
Expression analysis of chimeric RTB/p24 and p24 in E. coli Figure 2
Expression analysis of chimeric RTB/p24 and p24 in E. coli. Total proteins were extracted from E. coli cultures, sepa-
rated by 10% SDS-PAGE and stained with Coomassie. Protein profiles were analyzed after 5 h induction with (5 h+) or without 
IPTG (5 h-) and compared with non-induced cultures (T0). Four different E. coli strains were tested and these are indicated in 
the lower part of the panels. Panel A, p24 construct. The arrow indicates the expected band of about 34 kDa. Panels B and C, 
RTB/p24 construct. The arrows indicate the expected chimeric protein (RTB/p24) of about 57 kDa. The six E. coli strains 
employed are indicated at the bottom of panels. Panel D, western blot of RTB/p24 after expression at two temperatures (21°C 
and 37°C). We analyzed supernatant (S) and pellet (P) fractions for determination of soluble and insoluble fractions in E. coli 
cultures after 5 h induction. T0 represents non-induced cultures. Western blot was performed using anti-His monoclonal anti-
body at dilution of 1/1000. Panel E, analysis of different pH and NaCl concentrations on the lysis buffer to improve the solubil-
ity of RTB/p24 chimeric protein during affinity chromatography. Lanes 1 and 2 represent 1 ml aliquots of collected fractions. 
The arrows indicate the expected chimeric protein (RTB/p24). In all panels, M represents molecular weight markers in kDa.
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Biological activity of RTB/p24 in vitro
We measured affinity of RTB/p24 to the glycoprotein
asialofetuin by capture ELISA. The RTB/p24 fusion
showed a strong binding activity to asialofetuin, whereas
p24 presented only a residual binding activity which is
probably a nonspecific interaction (Figure 4). Our results
indicate that the affinity properties of RTB were not
altered by fusion to p24. On the contrary, the results sug-
gest that RTB/p24 retains a stable lectin-binding activity
with complex sugars. Binding to asialofetuin was further
confirmed by affinity column of immobilized asialofe-
tuin. The eluted fractions were tested with anti-ricin anti-
bodies and the 57 kDa band was again detected (Figure 5,
lanes 3 to 5). The anti-ricin antibodies also detected other
minor bands visible in the non-retained and wash frac-
tions (Figure 5, lanes 1 and 2). Their identity is unknown.
Immunization of mice with E. coli-based RTB/p24 induced 
strong immune responses against p24 HIV
We were interested to determine whether RTB could func-
tion as parenteral and mucosal adjuvant when fused to
p24. Groups of female BALB/c mice were inoculated i.p.
with varying amounts of the fusion in the presence of
complete Freund adjuvant (CFA). The adjuvant was
included as control since it is a potent, well-known adju-
vant. Two booster immunizations were performed using
incomplete Freund adjuvant (IFA) on days 15 and 30
post-priming. Sera were collected before each inoculation
and 15 days after the last immunization, and the level of
antibodies anti-p24 estimated by ELISA. It was found that
RTB/p24 was able to induce high levels of anti-p24 anti-
bodies (Figure 6). The antibody levels, induced in the
absence of any adjuvant, were comparable to the levels
induced by p24/CFA and RTB/p24 in the presence of CFA/
IFA. Core p24 alone did not induce significant levels of
antibodies (Figure 6).
To examine whether RTB could also act as an adjuvant in
mucosa, mice were inoculated i.n. following the same
schedule and doses as for i.p. immunizations, but using 5
μg of CT, a well-known mucosal adjuvant. Immunization
with RTB/p24, p24/CT and RTB/p24/CT induced antibod-
ies with a similar kinetics, reaching the highest levels by
day 15 and then remaining stable until the end of the
experiment (day 45). Mice immunized with p24 alone
also presented detectable levels of anti-p24 antibodies
that were increasing with succesive immunizations, albeit
at lower levels than in the other treatments (Figure 7). By
the day 15, the immune response to p24 alone was about
7-fold lower than in the other immunizations.
Purification of recombinant proteins expressed in E. coli and immunodetection Figure 3
Purification of recombinant proteins expressed in E. coli and immunodetection. Purification was performed as 
described in the text. Panel A, purified p24 (Lane 1) and purified RTB/p24 (Lane 2). Arrows indicate the expected proteins. 
Panel B, western blot of p24 purified protein, immunodetected with anti-p24 antibody at dilution of 1/1000. Panel C, western 
blot of purified RTB/p24 chimeric protein using three different antibodies, anti-p24 (1/1000), anti-His (1/1000), and anti-Ricin 
(1/3000). M, molecular weight markers in kDa. At the bottom a diagram of the two constructs is included.
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Discussion
The main goal of this work was to express, purify and test
the biological activity of a chimeric protein RTB/p24,
which could be used to enhance immune responses
against HIV-1 p24. RTB, which displays a single peptide
monomeric structure, facilitates translocation of mole-
cules into the cell by endocytosis through the cell mem-
brane via uncoated and clathrin-coated vesicles [18]. Both
p24 and RTB/p24 were readily produced in E. coli,
although with different solubility, contrasting the high
solubility of the p24 protein with the partial insolubility
of the chimeric RTB/p24. Different NaCl concentrations
and different pH were tested to improve solubility and
eventually it was found that high salt (300 mM) at pH 7
considerably improved solubilization of chimeric RTB/
p24. Once purified, RTB/p24 was easily resuspended in
PBS. Since proper folding of RTB is an important factor for
receptor binding [17,18], non-denaturing conditions
were employed throughout purification to keep the pro-
teins in native conformation. Non-glycosylated RTB/p24
showed a strong binding activity to asialofetuin in two dif-
ferent assays, capture ELISA and affinity chromatography.
These results suggest that RTB/p24 fusion protein did
retain proper conformation in E. coli in the absence of gly-
cosylation. Previously, it had been suggested that RTB
may retain its activity even when found in a non-glyco-
sylated form and fused to another protein as long as it
retains the proper conformation [19]. However, correct
conformation of recombinant RTB has not always been
achieved. When RTB was fused to the rotavirus antigen
NSP4, the fusion protein was denatured during purifica-
tion and even after renaturation, did it not bind asialofe-
tuin receptors as well as its native counterpart [17].
Our asialofetuin results also suggest that the chimeric pro-
tein retained heightened immunogenicity based on the
adjuvant properties of the genetically linked RTB. Indeed,
the presence of RTB markedly enhanced immune
responses in mice to p24 when administered i.p. and the
response was comparable to that obtained with p24 and
CFA, which is a strong parenteral adjuvant. Similarly, RTB
also enhanced immune responses to p24 in mice when
administered via the i.n. route. Nevertheless, this response
was not as strong as that obtained in mice immunized
with p24/CT. This is not surprising since CT is the
mucosal adjuvant of choice, however, its use is not
allowed in humans because of several side effects, such as
olfactory bulb inflammation and severe nasal discharges
[20]. Therefore, RTB seems to be a good candidate to
avoid these side effects without compromising its immu-
nostimulatory properties. Interestingly, CT did not
enhance antibody induction by RTB/p24 when both adju-
vants were combined. This was surprising as we had
hypothesized that the action of both mucosal adjuvants
could be synergistic. Synergy may occur with different
mucosal adjuvants, especially if they act via different
Functional assay of RTB/p24 chimeric protein Figure 4
Functional assay of RTB/p24 chimeric protein. Capture ELISA was performed using 20 μg of asialofetuin per well. Three 
concentrations of p24 and RTB/p24 were employed for the assay (1.0 μg, 0.5 μg, 0.25 μg, and 0.125 μg). As primary antibody, 
monoclonal anti-p24 was used at 1/500 dilution. Samples were done in triplicate and deviations are included.Virology Journal 2009, 6:17 http://www.virologyj.com/content/6/1/17
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receptors, but it does not happen in every instance [21].
CT binds GM1-ganglyoside receptors in cell membranes
of mammalian cells [22] whereas RTB contains two galac-
tose-binding domains and is able to bind asialo-sugar
membrane receptor molecules, including both glycolipids
and glycoproteins. [11,12]. Nasal-associated lymphoid
tissue contains specialized M cells, which can selectively
sample and internalize lectins in the nasal mucosa to be
presented to T cells by dendritic cells, macrophages and B
cells [23]. As it was shown in this report, the fusion pro-
tein RTB/p24 retained lectin activity and therefore, it is
likely that after i.n. administration, binding to M cells by
RTB increased the uptake and transport of p24 to the nasal
lymphoid tissue. On the other hand, we found an
enhanced immune response to p24 as early as the second
week after the first i.p. immunization with RTB/p24, in
comparison to mice immunized with p24 alone, which
induced modest anti-p24 antibodies levels at this same
timepoint. These results might be explained if administra-
tion of the fusion protein RTB/p24 in the peritoneal cavity
resulted in its transport to lymph nodes where the fusion
could be internalized by antigen presenting cells and pre-
sented to T and B cells.
There are some instances in which RTB has been used suc-
cessfully as a carrier fused to other molecules. For exam-
ple, RTB has been fused to two cytokines, the granulocyte
macrophage colony stimulating factor [24] and inter-
leukin 2 [25] and to the heavy chain of IgG [26]. It has
also been fused to the autoantigens proinsulin and
glutamic acid decarboxylase [27] and to rotavirus antigens
VP7 [28] and NSP4 [17]. The presence of RTB fused to
NSP4 resulted in higher levels of serum antibodies, which
is consistent with our results, confirming the immunos-
timulatory function of RTB via i.p. and mucosal routes.
The foreign molecule has been usually fused to the N-ter-
minal domain of RTB to avoid steric hindrance by the
antigen with RTB galactose receptor binding sites. In this
work, we fused p24 to the C-terminal domain of RTB and
our results demonstrate that apparently the position of
the foreign protein does not affect the carrier-adjuvant
abilities of RTB.
Since p24 is weakly immunogenic, adjuvant molecules
such as CT subunit B, HB core antigen and HSP70 from M.
tuberculosis have been employed to enhance presentation
of p24 to the immune system. These adjuvants were fused
to p24 and immune responses were reported, although
with HB core antigen only 90 aa out of 230 aa could be
fused to HB core antigen without compromising VLP for-
mation. In all three cases, a strong immune response in
mice was reported after i.p. administration, although CFA
had to be included with HB core-p24 in order to elicit a
response. In our case, fusion to RTB was enough to elicit a
Analysis by immunodetection of fractions from asialofetuin affinity chromatography Figure 5
Analysis by immunodetection of fractions from asialofetuin affinity chromatography. Five mg of the glycoprotein 
asialofetuin were immobilized on a 10 ml sepharose column. A total of 25 μg of RTB/p24 purified protein were loaded on to 
the column. Lane 1, protein not retained by the asialofetuin-sepharose column. Lane 2 column washes. Lane 3 through 5, frac-
tions retained on the column. Immunodetection was performed using the anti-ricin polyclonal antibody at 1/2000 dilution. The 
arrow indicates the expected protein (57 kDa).Virology Journal 2009, 6:17 http://www.virologyj.com/content/6/1/17
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strong immune response to p24 via i.p. and intranasal
routes, and the levels of antibodies induced were compa-
rable to those induced in the presence of a CFA.
This is the first report in which a eukaryotic toxin pro-
duced in E. coli is employed as an adjuvant to elicit
immune responses to p24 HIV core antigen. The high lev-
els of antibodies obtained after i.n. and i.p. immunization
with RTB/p24 should encourage the use of ricin toxin B
subunit protein to enhance immune responses against
other HIV antigens, with special emphasis in evocating
cytotoxic T-lymphocyte responses, which are likely to be
an important component of any HIV vaccine candidate.
Conclusion
We report for the first time the adjuvant properties of Rici-
nus communis toxin B subunit when fused to p24 HIV-1
protein. The chimeric protein was expressed in E. coli and
purified by affinity chromatography. Yields of p24 and
RTB/p24 were estimated to be 4.6 mg/l and 0.63 mg/l
respectively. By using the glycoprotein asialofetuin, in
capture ELISA and sepharose affinity chromatography
assays, we were able to demonstrate binding of the fused
protein RTB/p24 to complex sugars, confirming a stable
lectin activity. The chimeric protein was able to induce a
strong immune response as demonstrated by the mice
immunization experiments. Only two weeks after i.p.
inoculation with RTB/p24, mice developed a strong anti-
p24 antibody response, without the need of an exogenous
adjuvant. Intranasal inoculation with RTBp24, triggered
levels of anti-p24 antibodies comparable to those
obtained by immunization with p24 alone in the pres-
ence of cholera toxin. Our results demonstrate that ricin
toxin B subunit is an excellent candidate to enhance
immunogenicity at the i.p. and i.n. routes of HIV, and
probably other, antigens, and potentially to boost cyto-
toxic T-lymphocyte responses in the context of mucosal
protection, a major requirement for a potential HIV vac-
cine candidate.
Materials and methods
Construction of RTB/p24 and p24 genes
Based on the published sequence of proricin (GenBank
S40366) [9], we designed primers to amplify RTB using
genomic DNA from R. communis as template since lectins
do not contain introns. The forward (5' CCG CAT GAA
TTC ATG GCT GAT GTT TGT ATG GAT CCT GAG CCC
ATA 3') and reverse primers (5' ACC TGC CTA TCA CTC
GAG AAA TAA TGG TAA CCA TAT TTG GTT 3') incorpo-
rated EcoRI and XhoI sites at the 5' and 3'ends respectively.
The DNA coding for HIV-1 p24 was amplified by PCR
using a cDNA encoding gag as template, kindly provided
Levels of IgG antibodies anti-p24 after intraperitoneal immunization Figure 6
Levels of IgG antibodies anti-p24 after intraperitoneal immunization. BALB/c mice were immunized at the days indi-
cated by arrows, with 15 μg of p24 (filled squares) or 30 μg of RTB/p24 in the presence (filled triangles) or absence (open tri-
angles) of CFA/IFA. As negative control mice were inoculated with PBS (filled rhombus). Serum samples were diluted at 1/200, 
and levels of IgG anti-p24 antibodies were determined by ELISA. All sera samples were tested in triplicate and standard devia-
tions are included.Virology Journal 2009, 6:17 http://www.virologyj.com/content/6/1/17
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by Dr. Yong Kang (University of Western Ontario), using
a forward (5' GTC GAC CCT ATA GTG CAG AAC 3') and
reverse primers (5' AAG CTT TCT AGA TTA TTA CAA AAC
TCT TGC TTT ATG 3'), incorporating SalI, HindIII and
XbaI sites. After cloning the PCR products in the Topo 2.1
vector, p24 was cloned downstream of RTB by ligating the
XhoI site on the 3' extreme of RTB to the SalI site at the 5'
of the p24 sequence (Figure 1B). The RTB/p24 fusion was
cloned into the flanking sites EcoRI and HindIII of the E.
coli expression vector pTrcHisA, which directs gene expres-
sion with the trc (trc-lac) promoter. In addition, p24 alone
was also cloned in the vector pTrcHisA, at the XhoI and
HindIII sites (Figure 1A). Both genes inserted into the
expression vector were sequenced to confirm in-frame
cloning. The pTrcHis vector contains a histidine tag
employed for affinity chromatography purification.
E. coli expression of RTB/p24 and p24 HIV proteins
Six E. coli strains were tested to obtain the best levels of
expression and solubility of the RTB/p24 and p24 pro-
teins in cytosolic fractions: HMS 174, HMS Rosetta 2,
HMS LysE, BL21 Rosetta 2, Rosetta-gami and RP2. Two
temperatures, 21°C and 37°C, were also tested accord-
ingly. A single colony harboring the plasmid was inocu-
lated on 25 ml of LB media in the presence of ampicilin
(100 mg/l), and cultivated overnight at 37°C. The culture
was transferred to 250 ml of LB medium and incubated to
an OD600 of 0.5–0.7; after that, recombinant proteins
synthesis was induced with IPTG (0.5 mM) during 5 to 7
h. Cells were harvested by centrifugation at 4000 rpm for
15 minutes. Cellular fractions of pellet and supernatant
were diluted in Laemmli loading buffer, boiled at 95°C
for 5 min and analyzed by SDS-PAGE and Coomassie blue
staining.
Purification of recombinant proteins
After recombinant protein induction, cellular pellets were
resuspended in lysis buffer. We tested four different con-
centrations of NaCl (50, 75, 150 and 300 mM) and four
pH conditions (pH 6, 7, 8 and 9), in the lysis buffer to
obtain optimal solubilization of the recombinant RTB/
p24 protein during affinity chromatography. Thus, cellu-
lar pellets were resuspended in the standarized lysis buffer
(50 mM TrisHCl pH 7.0, 300 mM NaCl, 20 mM Imida-
zole, 1 mM PMSF, 1 mg/ml lysozyme). Protein extracts
were incubated for 30 min at 4°C. Lysis was performed by
the freeze-thaw lysozyme procedure as described previ-
ously [17]. Following centrifugation at 12000 rpm for 30
min, protein soluble fractions were filtered using a 0.4 μM
Millipore filter and immediately passed through a Nickel-
sepharose column (General Electric, US). Columns were
pre-equilibrated with binding buffer (50 mM TrisHCl,
300 mM NaCl and 20 mM Imidazole pH 7.0). Extensive
washes with binding buffer were applied to remove non-
Levels of anti-p24 antibodies after intranasal immunization with p24 and RTB/p24 Figure 7
Levels of anti-p24 antibodies after intranasal immunization with p24 and RTB/p24. BALB/c mice were intranasally 
inoculated at the days indicated by arrows with PBS plus 5 μg of CT (filled rhombus), p24 (filled squares), p24 mixed with 5 μg 
of CT (open squares), RTB/p24 (filled triangles) and RTB/p24 supplemented with 5 μg of CT as adjuvant (open triangles). 
Serum samples were diluted at 1/200, and levels of IgG anti-p24 were determined by ELISA. Analysis was performed in dupli-
cate and all sera samples were analyzed in triplicate and standard deviations included.Virology Journal 2009, 6:17 http://www.virologyj.com/content/6/1/17
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specific protein interactions using the previously
described binding buffer supplemented with 40 mM Imi-
dazole. His-tagged recombinant proteins were recovered
by application of binding buffer containing 500 mM Imi-
dazole. The recovered fractions were dialyzed in PBS pH
7.4 overnight.
Protein analysis
Protein concentration was estimated by using the Brad-
ford reagent (Sigma). Recombinant proteins were sub-
jected to western blot for immuno-detection.
Consequently, proteins were transferred from the SDS gel
(10%) on to a PVDF membrane (Amersham) and probed
with antibodies, after overnight incubation with skim
milk at 5% in TTBS buffer (100 mM TrisHCl pH 7.5, 150
mM NaCl, and 0.05% Tween-20). Mouse anti-HIS anti-
bodies (Roche) were diluted in TTBS at 1/1000 and
hybridized with the membrane for 1 h, at room tempera-
ture. Also, rabbit anti-Ricin antibodies (Sigma) at 1/3000
and mouse anti-p24 antibodies (Millipore) at 1/1000
dilutions were used for detection of recombinant pro-
teins. After incubation, the membrane was washed three
times for 10 min each and the secondary antibodies,
diluted to 1/10,000, were added and incubated for an
additional h at room temperature.
Evaluation of biological activity of RTB/p24 in vitro
Interaction between the glycoprotein asialofetuin and
RTB/p24 chimeric protein was analyzed by binding
ELISA. Microtiter plates (Costar) were coated with 20 μg
per well of asialofetuin (Sigma) in bicarbonate buffer (15
mM Na2CO3, 35 mM NaHCO3, pH 9.6). Binding was
done overnight at 4°C. After blocking with PBS-5% skim
milk (PBSM) for 2 h at room temperature, known quanti-
ties of purified RTB/p24 and p24 proteins (1 μg, 0.5 μg,
and 0.125 μg) were added to the plates in triplicate and
incubated overnight at 4°C. Plates were washed with PBS-
0.05% Tween-20 (PBST) and, after adding the anti-p24
monoclonal antibody at 1/500 in PBSM, they were incu-
bated at 37°C for 2 h. Following three washes with PBST,
anti-mouse HRP conjugated secondary antibody was
added at 1/2500 in PBSM and the plates were incubated
at 37°C for 2 h. Following 3 washes with PBST, plates
were coated with 100 μl of peroxidase TMB substrate
buffer (Sigma), incubated for 15 min at room temperature
and the reaction stopped with 50μl of 1 N H2SO4, and
read at 450 nm. An additional experiment to evaluate
interaction between RTB/p24 and asialofetuin was per-
formed. We prepared a sepharose column for affinity
chromatography with immobilized asialofetuin. Five mg
of asialofetuin were diluted in 0.1 M NaHCO3 and 0.5 M
NaCl buffer, pH 8.3 and the solution was employed for
immobilization of asialofetuin in Cyanogen bromide-
activated-sepharose (Sigma), which (1 g) had been
hydrated and washed with 200 ml of 1 mM HCl. Follow-
ing blocking with 0.2 M glycine pH 8.0 overnight, the
resin was extensively washed with 0.1 M sodium acetate/
0.5 M NaCl pH 4.0 and with 0.1 M Tris HCl/0.5 M NaCl
pH 8.0, in five intervals. Subsequently, the resin was
loaded onto the sepharose column. About 25 μg of
recombinant, purified RTB/p24 in 20 ml of PBS were
loaded on to a column containing the sepharose with the
immobilized asialofetuin. The column was washed with
eight ml of buffer A (50 mM TrisHCl, 5 mM EDTA, 150
mM NaCl, and 0.1% Tween-20 pH 7.8). Following a wash
with 10 ml of buffer B (50 mM TrisHCl, 5 mM EDTA, pH
7.8), proteins were eluted in 3 fractions of 1 ml each using
elution buffer (100 mM Glycine pH 4.0). Fractions were
collected on tubes containing a neutralization solution
buffer (200 mM Tris HCl, pH 9.0).
Immunization of mice
Groups of six female 6–8 week-old BALB/c mice were
inoculated intraperitoneally (i.p.) or intranasally (i.n.)
with purified RTB/p24 and p24 recombinant proteins in
PBS. Mice were immunized i.p. in a volume of 200 μl,
with the following doses per group: PBS, 15 μg of p24, 30
μg of RTB/p24, 15 μg of p24 plus complete Freund's adju-
vant (CFA), and 30 μg of RTB/p24 with CFA. Mice were
boosted on days 15 and 30 using the same protocol,
except that incomplete Freund's adjuvant (IFA) was used
instead of CFA. We used 30 μg of the fusion protein RTB/
p24 since RTB and p24 are present in equimolar propor-
tion in the chimeric protein. For i.n. immunization,
groups of six BALB/c mice were anesthetized with 25 μg of
sodium phenobarbital in 0.2 ml of PBS per mouse,
administered intraperitoneally. Recombinant protein
doses were administered in a volume of 30 μl of PBS, as
follows: PBS containing 5 μg of CT adjuvant (Sigma), 15
μg of p24, 30 μg of RTB/p24, 15 μg of p24 mixed with 5
μg of CT and, 30 μg of RTB/p24 mixed with 5 μg of CT
adjuvant. Intranasal immunizations were performed
using the same protocol as that for i.p. immunizations. All
mice were bled before each inoculation and 15 days after
the last immunization. Blood samples were kept at 4°C
for 2 h, and serum was obtained by centrifugation at 4000
rpm for 10 min, at 4°C.
Determination of mice Ab levels to RTB/p24 and p24 
recombinant proteins
The levels of IgG antibodies anti-p24 were analyzed by
ELISA during the time course of immunizations. A prelim-
inary ELISA was performed to determine the optimal con-
centration of the purified p24 antigen and the best mice
serum dilutions. We prepared serial dilutions, ranging
from 1 μg to 0.00781 μg in triplicate wells and the protein
was detected using three dilutions of the commercial
monoclonal mouse anti-p24 antibody (1/500, 1/1000
and 1/2000). Data of p24 concentration were plotted
against mice serum dilutions (data not show). From thisVirology Journal 2009, 6:17 http://www.virologyj.com/content/6/1/17
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experiment, we decided to employ 0.2 μg of p24 and to
test mice serum samples at a dilution of 1/200 in subse-
quent experiments. Microtiter plates were coated with 200
ng/well of purified p24 in 50 μl of PBS and incubated at
4°C overnight. Following three washes with 150 μl/well
of PBST, wells were blocked with 200 μl/well of PBSM for
2 h at room temperature. Plates were washed with PBST
before addition of 50 μl/well of the serum samples at a
dilution of 1/200 in PBSM. Plates were incubated at 37°C
for 1 h, the wells washed extensively with PBST and 50 μl
of HRP-conjugated, anti-mouse IgG secondary antibody
diluted at 1/2500 in PBSM added to the wells. Four final
washes with PBSM were given prior to addition of 50 μl/
well OPD peroxidase substrate (Sigma). After incubation
at room temperature for 8–10 min color development was
read at 492 nm in an ELISA plate reader (Multiskan, Lab-
system). The levels of anti-p24 antibody were determined
in each serum sample and the values were used for estima-
tion of standard deviations. All serum samples were ana-
lyzed in triplicate and the results were plotted to
determine the anti-p24 antibody levels.
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